Physician profile
Ryan Michael Pulham
NPI 1437811585
$2,768.55
in general payments reported to CMS, 2019-2025
34 companies · $924 in 2025
The $924 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.47 · 2022: $441 · 2023: $730 · 2024: $662 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,316.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $725.42 | 2022-2025 | |
| Lilly USA, LLC | $364.71 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $180.30 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $149.50 | 2023-2025 | Shingrix, Arexvy |
| Alkermes, INC. | $135.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $121.87 | 2022-2024 | Spravato |
| Pfizer INC. | $100.70 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.17 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $79.77 | 2022-2025 | Capvaxive, Gardasil 9, Enflonsia |
| Cranial Technologies, INC | $75.96 | 2023-2024 | Doc Band |
| Edwards Lifesciences Corporation | $72.51 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $62.30 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Organon LLC | $57.85 | 2022-2025 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $54.54 | 2022-2024 | |
| Sanofi Pasteur INC. | $54.00 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.56 | 2025 | Airsupra |
| Corcept Therapeutics | $44.78 | 2025 | Korlym |
| Boston Scientific Corporation | $40.82 | 2024 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $32.99 | 2022 | |
| Exact Sciences Corporation | $31.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biomerieux INC | $28.00 | 2025 | Biofire Spotfire Control Station |
| Neuronetics, INC. | $23.06 | 2025 | Neurostar Tms Therapy System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.06 | 2025 | Xifaxan |
| Dexcom, INC. | $19.73 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $19.41 | 2022 | |
| Corium, LLC | $18.50 | 2024 | Azstarys |
| Dynavax Technologies Corporation | $18.13 | 2023 | Heplisav-B |
| Currax Pharmaceuticals LLC | $17.35 | 2023 | Contrave |
| Neurocrine Biosciences, INC. | $15.64 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.38 | 2023 | Seglentis, Livalo |
| Seqirus USA INC | $14.46 | 2022 | |
| Neurelis, INC. | $12.41 | 2022 | |
| Collaborative Care Diagnostics, LLC | $12.07 | 2023 | |
| Eisai INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Pulham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.